NCT01435772
Pompe Disease
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
All
From 13 Years
No
BMN 701
Phase 2
Interventional
21
2011-08-15
2018-05-22
San Diego, California, United States
Gainesville, Florida, United States
Tampa, Florida, United States
Kansas City, Kansas, United States
Herston, Queensland, Australia
North Adelaide, South Australia, Australia
Paris, , France
Mainz, , Germany
Auckland, , New Zealand
Birmingham, , United Kingdom
London, , United Kingdom
Salford, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields